Ladies and Gentleman,

First of all, please let me thank you for your commitment and positive spirit. In the past few months, we have proved once again how fundamentally strong the Elanix team is and how determined we are despite all the difficulties encountered in our day-to-day work.

I would like to share an overview of our second quarter with you, as well as further details on where we have reached and progress we have made.

As of June 11, we formally closed a capital increase (private placement). All 679,920 offered shares were placed at a subscription price of EUR 1.28, resulting in gross proceeds of EUR 870,298. As a result of the cash capital increase, the share capital of Elanix will increase to a total of 7,779,139 shares. Among other things, the gross proceeds will be used to finance the company’s growth strategy and, especially, for the market launch of new Advanced Skin Care products. The capital increase is also intended to solidify the company’s capital base.

We strengthened our management team with the appointment of Egon Minar as Chief Operating Officer and Chief Financial Officer. Egon will oversee the company’s finances, support our financing and investor relations activities, and will be responsible for the day-to-day operations of the organization. He brings four decades of management experience and his leadership will be an essential asset at this stage of Elanix’ growth. We wish him a warm welcome. Read more about Egon here:

We signed an agreement appointing Lexel Pharma SA as a new Sales Representative for the French-speaking region of Switzerland or Suisse Romande on May 11, 2018. Lexel’s sales force will work closely with gynecologists to strengthen our retail network in this key territory which is also the birthplace of our company.

We received ISO 9001:2015 certification for our Advanced Skin Care subsidiary, Repair-A SA, which is responsible for the development and marketing of Elanix’s progenitor cell based CFPC® creams, GYNrepair® and SKINrepair®.

We also signed a distribution agreement with Moscow-based company MedBioSante. Through this partnership, Elanix will initially sell its products via a gynecologist prescription-network in Moscow before extending its reach through digital sales channels to other Russian cities and the CIS from next year. We have had excellent feedback from GYNrepair trials carried-out under gynecological supervision, and we look forward to entering this new market by end of June.

We have been attending European Wound Care events including the European Wound Management Association conference in Krakow (EWMA 2018) and the World Advanced Therapies & Regenerative Medicine congress in London. This was a great opportunity to network with industry leaders and keep updated on the latest trends in wound management and regenerative medicine.

Last week, we re-launched our GYNrepair website with improved functionality and enriched content. Please see more at :

Over the next few months, we will produce a series of short videos that present Elanix through the eyes of those who work here. For the first in our “Meet the Team” series, we sat down with Elanix CTO Geofrey De Visscher. Watch the full interview here:

With best wishes,

Tomas J. Svoboda, CEO

Nyon, June 14 2018